Recently, dabigatran was approved for stroke prevention in the AF population, followed closely by rivaroxaban. Apixaban is also currently undergoing FDA review. The following is a summary of these new warfarin rivals.
Recently, dabigatran was approved for stroke prevention in the AF population, followed closely by rivaroxaban. Apixaban is also currently undergoing FDA review. The following is a summary of these new warfarin rivals.
Recently, dabigatran was...